AstraZeneca reports strong nine-month and Q3 2025 financial results
Pharmaceutical company AstraZeneca announced robust financial results for the first nine months and the third quarter of 2025. The company reported significant revenue and earnings growth, driven by strong commercial performance and pipeline advancements.
AstraZeneca has reported strong financial results for the first nine months and the third quarter of 2025, ending September 30. The company's total revenue increased by 10% year-on-year for the nine-month period and by 12% for the third quarter.
The reported earnings per share (EPS) saw substantial growth, rising 43% for the nine months and 77% for the third quarter. Core EPS, which excludes certain items, grew by 15% over the nine-month period and 14% in the third quarter. The company attributed this performance to solid commercial execution and significant progress in its research and development pipeline.
Chief Executive Officer Pascal Soriot stated that the company is well-positioned to sustain growth through 2026 and achieve its 2030 ambition. He highlighted the announcement of 16 positive Phase III trial readouts this year, including key results for baxdrostat and Enhertu. AstraZeneca is also strengthening its US operations through an agreement to lower medicine costs for American patients and by breaking ground on a new $4.5 billion manufacturing facility in Virginia.
Throughout the year, AstraZeneca has achieved several regulatory approvals and submissions across major markets. The company reiterated its guidance for FY2025, expecting total revenue to increase by a high single-digit percentage and core EPS to grow by a low double-digit percentage at constant exchange rates.